Ligand Pharmaceuticals (NASDAQ:LGND) reported quarterly earnings of $1.63 per share which missed the analyst consensus estimate of $1.82 by 10.44 percent. This is a 22.56 percent increase over earnings of $1.33 per share from the same period last year. The company reported quarterly sales of $51.722 million which missed the analyst consensus estimate of $58.696 million by 11.88 percent. This is a 14.09 percent increase over sales of $45.333 million the same period last year.